VEGFA and neoplasm: Arsenic trioxide, an anticancer agent, disrupts the HIF-1α–VEGF–ANG axis by inhibiting PI3K-Akt/HIF-1α signaling, thereby limiting the paracrine activity of ANG 1 and ANG 2 [133], resulting in the inhibition of angiogenesis and tumor growth.